Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
16.9.2021 15:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1::pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMAKRAS™ (sotorasib), the first US Food and Drug Administration (FDA) approved KRASG12C inhibitor for adult patients with locally advanced or metastatic non-small cell lung cancer. The trial will investigate potential synergistic effects of this combination, possibly improving therapeutic outcomes beyond those of KRASG12C inhibitor therapy alone, specifically for people living with lung and colorectal cancers.
Preclinical data suggest that the combination of a KRASG12C inhibitor with a SOS1::pan-KRAS inhibitor may result in increased anti-tumor activity in KRAS G12C-driven cancers based on the complementary mechanisms of these targeted oncology agents.1 2 By shifting the equilibrium from active KRAS towards the inactive form, SOS1::pan-KRAS inhibitors have the potential to sensitize KRAS G12C-mutant tumors to covalent KRASG12C inhibitors that bind to inactive KRAS. In addition, SOS1 inhibitors block feedback reactivation which occurs upon pathway inhibition.
“We are excited to partner with Amgen, who have pioneered KRAS G12C inhibition, and to further expand our program to make a difference for people living with KRAS-driven cancers,” said Francesco Di Marco, Ph.D., Corporate Senior Vice President, Global Therapy Area Head Oncology at Boehringer Ingelheim. “Boehringer Ingelheim follows an ‘all-in’ research approach to taking cancer on, including the first and most advanced SOS1::pan-KRAS inhibitor which we investigate in several combinations and cancer types to realize even more opportunities to deliver potential therapeutic benefits to cancer patients.”
Under the terms of the non-exclusive collaboration, Amgen will be the sponsor of the trial and Boehringer Ingelheim and Amgen will jointly share the costs of and oversee clinical development for the combined therapy.
About BI 1701963
BI 1701963 is an investigational, orally available small molecule, that binds to the catalytic domain of SOS1 preventing the interaction with inactive KRAS. This reduces the formation of active KRAS and in consequence inhibits MAPK pathway signaling in KRAS-dependent cancers. SOS1 inhibition also simultaneously blocks feedback driven reactivation of the MAPK pathway. The selective inhibition of SOS1 is a therapeutic concept that could allow KRAS blockade irrespective of KRAS mutation type (pan-KRAS approach). SOS1::KRAS inhibitors exhibit activity on a broad spectrum of KRAS alleles, including all major G12D/V/C and G13D oncoproteins, as published by Hofmann MH, et al. in Cancer Discovery, a journal of the American Association of Cancer Research (AACR). BI 1701963 is currently being evaluated in phase I clinical trials in patients with advanced KRAS-mutated cancers to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of BI 1701963 alone and in combination with MEK inhibitors, KRASG12C inhibitors or irinotecan.
Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/clinical-collaboration-amgen
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005436/en/
Contact information
Media Contacts:
Boehringer Ingelheim
Sarah Soetbeer
Junior Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-183874
press@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Strengthens Presence in India with JMP Advisors18.6.2026 15:00:00 EEST | Press release
Andersen Global enters into a Collaboration Agreement with JMP Advisors in India, adding tax capabilities to its existing legal capabilities in the country. Providing advice across tax, regulatory and transaction matters, JMP Advisors serves domestic and multinational clients operating in complex and evolving business environments. The firm provides services spanning international and Indian domestic tax, transfer pricing, cross-border structuring, foreign investment advisory, transaction support, succession planning and regulatory matters. Its clients include multinational corporations, growing enterprises, private equity and venture capital-backed businesses, and high-net-worth individuals and families. “Our approach has always centered on delivering clear, actionable guidance that helps clients navigate complex situations and continue their business with a clear sense of direction,” said Jairaj Purandare, founder and chairman of JMP Advisors Private Limited. “Collaborating with Ande
IFCO Launches TRLLN, a Pioneering Tracking-as-a-Service Solution for Global Asset Visibility18.6.2026 13:55:00 EEST | Press release
IFCO, a global leader in reusable packaging solutions for the fresh food supply chain, is launching TRLLN (pronounced “trillion”), a standalone technology venture designed to help companies improve visibility across large, fast-moving asset networks. Unlike traditional tracking models that often require gates, scanners, or fixed hardware installations along the supply chain, TRLLN’s infrastructure-free approach allows companies to deploy asset tracking significantly faster and with less operational complexity. TRLLN’s platform addresses four core visibility questions across industries: where the asset is, whether it is in the right condition, whether it has reached the right destination, and what its full movement history shows. While use cases differ by sector, the technology can be applied across a wide range of industries. TRLLN brings proven asset tracking hardware and software technology to companies managing large networks of reusable and mobile assets, including pallets, contain
NIQ and Ogury Collaborate to Enhance Media Planning and Audience Strategy with GeoPurchase Insights18.6.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), the world’s leading consumer intelligence company, today announced a new collaboration with Ogury, the global AdTech company powered by Persona Intelligence. Through the collaboration, Ogury will integrate NIQ’s GeoPurchase data into its Persona Intelligence Engine, strengthening audience planning, media activation, and strategic insights for marketers. NIQ delivers world-leading retail intelligence, capturing actual purchase data at the product level across key retailers around the world. Through this collaboration, NIQ is providing GeoPurchase insights at scale across France, Germany, Spain, Italy, the UK, as well as the United States and Canada, bringing a new layer of real-world retail purchase behavior into Ogury’s Persona Intelligence Engine. Combined with Ogury’s audience-first data model—which brings together observed behaviours, declared intents, and deterministic signals—these insights help create rich, multi-dimensional personas informed by actual purchasing
Linvo Sets Sights on AI-Led Wealth Management, Opens AI Advisor Roles for 202618.6.2026 12:40:00 EEST | Press release
Linvo AG, a Zurich-based multi-family office and wealth management firm, today set out its vision for the year ahead, naming applied artificial intelligence as the centre of its strategy for 2026 and opening a new set of AI advisor roles to deliver it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618933521/en/ Linvo sets sights on AI-led wealth management, opens AI advisor roles for 2026 The firm sees the coming year as the point at which AI moves from a support tool to a core discipline within wealth management — shaping how portfolios are analysed, how clients are served, and how advisory teams spend their time. The new AI advisor roles are intended to anchor that shift inside the firm. "2026 is the year we stop treating AI as an add-on and start treating it as a discipline in its own right," said Alexander Kogan, Director at Linvo. "Hiring AI advisors is how we build that future deliberately, rather than leaving it t
Frost & Sullivan 2026 Technology Innovation Leadership Best Practices Recognition for Ohmium International18.6.2026 11:31:00 EEST | Press release
Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has received the 2026 Global Technology Innovation Leadership Recognition for Best Practices in the PEM electrolyzer and green hydrogen industry by Frost & Sullivan. This recognition highlights Ohmium's continued advancement of cutting-edge PEM technology into scalable, real-world hydrogen solutions that address critical energy and industrial challenges across global markets. Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition for Best Practices to organizations that demonstrate exceptional achievement in leveraging technology to drive market transformation and measurable business impact. The firm evaluates companies across two core dimensions: technology leverage and business impact. Ohmium excelled across both measures, demonstrating commitment to innovation, stage gate efficiency, commercialization, and applic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom